Hikma Pharmaceuticals Executive Discloses Share Disposal under Regulatory Framework

Strategic Insights -

Hikma Pharmaceuticals, a major player in the pharmaceuticals sector, has reported a significant transaction involving one of its top executives, Dr. Bill Larkins. The disposal of shares was officially notified under the EU's Market Abuse Regulation 596/2014, integrated into domestic law by the European Union (Withdrawal) Act 2018. On June 4, 2025, Dr. Larkins sold 5,257 shares on the London Stock Exchange at a price of APS21.28 per share, totaling APS111,868.96. This transaction was disclosed to ensure transparency in the market, as mandated by Article 19(3) of the Market Abuse Regulation.

Key Takeaways:

  • Dr. Bill Larkins, a Person Discharging Managerial Responsibilities (PDMR), sold 5,257 shares of Hikma Pharmaceuticals PLC on the London Stock Exchange on June 4, 2025.
  • The shares were disposed of at a price of APS21.28 per share, amounting to a total transaction value of APS111,868.96.
  • The transaction was disclosed to comply with Article 19(3) of the Market Abuse Regulation and ensure transparency in the market.
  • Hikma Pharmaceuticals PLC has reiterated its commitment to upholding high standards of corporate governance and regulatory compliance across all jurisdictions it operates in.
  • The company's Group Company Secretary, Helen Middlemist, can be contacted for further information at +44 (0) 20 7399 2760.

Statistics:

  • 5,257 shares were sold by Dr. Bill Larkins on June 4, 2025.
  • The shares were sold at a price of APS21.28 per share.
  • The total transaction value was APS111,868.96.
  • Hikma Pharmaceuticals PLC operates listed on both the London Stock Exchange under the ticker HIK and Nasdaq Dubai.

Sources:

  • Nasdaq Dubai - Hikma Pharmaceuticals PLC listing information.
  • Hikma Pharmaceuticals PLC - Regulatory notification regarding Dr. Bill Larkins' share disposal (referenced as Article 19(3) of the Market Abuse Regulation).
  • European Union (Withdrawal) Act 2018 - Integrated regulatory framework for the EU Market Abuse Regulation 596/2014.